This document outlines the serum banking policy at UW for research and support staff.
Log of updates to the UW Biosafety Manual
Complete the Clinical Trial Biological Use Authorization (BUA) Application for new and renewal projects to obtain approval for research involving recombinant DNA in human subjects. Submit Clinical Trial BUA applications at least eight weeks prior to the IBC meeting. Electronic submissions to ehsbio@uw.edu are preferred. Submit via campus mail to EH&S at Box 357165 or by fax to 206.221.3068.
During 2017's National Biosafety Month, you are encouraged to focus attention on biosafety policies, practices and procedures. Investigators and laboratory managers should raise biosafety awareness, discuss the importance of safety, and seek input on ways to strengthen biosafety practices and procedures in their labs. This year, EH&S is focusing on sharps safety in research and exposure response.
Drugs are classified as hazardous if they may cause cancer, developmental or reproductive toxicity or harm to organs at low doses. They include drugs used for cancer chemotherapy (also called antineoplastics), antiviral drugs, hormones, some bioengineered drugs and other various drugs.
Check the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 to determine if a drug is classified as hazardous.